Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Possibility of molecular targeting therapy for the treatment of cancer of unknown primary origin by analysis of intracellular signaling molecules.

Ohta S, Cho Y, Shibata M, Nagai K, Iijima T, Saito H, Asakura H, Kojima H.

Exp Ther Med. 2012 Mar;3(3):547-549. Epub 2011 Dec 14.

2.

[Detection of KRAS, BRAF, PIK3CA and EGFR gene mutations in colorectal carcinoma].

Ling Y, Ying JM, Qiu T, Shan L, Guo L, Lü N.

Zhonghua Bing Li Xue Za Zhi. 2012 Sep;41(9):590-4. doi: 10.3760/cma.j.issn.0529-5807.2012.09.004. Chinese.

PMID:
23157825
3.

Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.

Pentheroudakis G, Kotoula V, De Roock W, Kouvatseas G, Papakostas P, Makatsoris T, Papamichael D, Xanthakis I, Sgouros J, Televantou D, Kafiri G, Tsamandas AC, Razis E, Galani E, Bafaloukos D, Efstratiou I, Bompolaki I, Pectasides D, Pavlidis N, Tejpar S, Fountzilas G.

BMC Cancer. 2013 Feb 2;13:49. doi: 10.1186/1471-2407-13-49.

4.

Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.

László L.

Magy Onkol. 2010 Dec;54(4):383-94. doi: 10.1556/MOnkol.54.2010.4.13.

5.

Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases.

Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE.

Clin Cancer Res. 2010 Feb 1;16(3):790-9. doi: 10.1158/1078-0432.CCR-09-2446. Epub 2010 Jan 26.

6.

Characteristics and prevalence of KRAS, BRAF, and PIK3CA mutations in colorectal cancer by high-resolution melting analysis in Taiwanese population.

Hsieh LL, Er TK, Chen CC, Hsieh JS, Chang JG, Liu TC.

Clin Chim Acta. 2012 Oct 9;413(19-20):1605-11. doi: 10.1016/j.cca.2012.04.029. Epub 2012 May 8.

PMID:
22579930
7.

Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?

Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.

Genet Med. 2013 Jul;15(7):517-27. doi: 10.1038/gim.2012.184. Epub 2013 Feb 21.

PMID:
23429431
8.

Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.

Tabernero J, Lenz HJ, Siena S, Sobrero A, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Yoshino T, Goldberg RM, Sargent DJ, Wagner A, Laurent D, Teufel M, Jeffers M, Grothey A, Van Cutsem E.

Lancet Oncol. 2015 Aug;16(8):937-48. doi: 10.1016/S1470-2045(15)00138-2. Epub 2015 Jul 13.

PMID:
26184520
9.

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S.

Lancet Oncol. 2010 Aug;11(8):753-62. doi: 10.1016/S1470-2045(10)70130-3. Epub 2010 Jul 8.

PMID:
20619739
10.

EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases.

Schmid K, Oehl N, Wrba F, Pirker R, Pirker C, Filipits M.

Clin Cancer Res. 2009 Jul 15;15(14):4554-60. doi: 10.1158/1078-0432.CCR-09-0089. Epub 2009 Jul 7.

11.

A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer.

Kawazoe A, Shitara K, Fukuoka S, Kuboki Y, Bando H, Okamoto W, Kojima T, Fuse N, Yamanaka T, Doi T, Ohtsu A, Yoshino T.

BMC Cancer. 2015 Apr 11;15:258. doi: 10.1186/s12885-015-1276-z.

12.

The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.

Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M.

Acta Oncol. 2014 Jul;53(7):852-64. doi: 10.3109/0284186X.2014.895036. Epub 2014 Mar 25. Review.

PMID:
24666267
13.

Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine.

Shen Y, Wang J, Han X, Yang H, Wang S, Lin D, Shi Y.

PLoS One. 2013 Dec 10;8(12):e81628. doi: 10.1371/journal.pone.0081628. eCollection 2013.

14.

High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer.

Guedes JG, Veiga I, Rocha P, Pinto P, Pinto C, Pinheiro M, Peixoto A, Fragoso M, Raimundo A, Ferreira P, Machado M, Sousa N, Lopes P, Araújo A, Macedo J, Alves F, Coutinho C, Henrique R, Santos LL, Teixeira MR.

BMC Cancer. 2013 Apr 1;13:169. doi: 10.1186/1471-2407-13-169.

15.

[Molecular biological diagnostics of KRAS and BRAF mutations in patients with colorectal cancer - laboratory experience].

Robešová B, Bajerová M, Vašíková A, Ostřížková L, Hausnerová J, Kyclová J, Pospíšilová S, Mayer J, Dvořáková D.

Klin Onkol. 2013;26(1):25-30. Czech.

PMID:
23528169
16.

PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer.

Sood A, McClain D, Maitra R, Basu-Mallick A, Seetharam R, Kaubisch A, Rajdev L, Mariadason JM, Tanaka K, Goel S.

Clin Colorectal Cancer. 2012 Jun;11(2):143-50. doi: 10.1016/j.clcc.2011.12.001. Epub 2012 Jan 28.

17.

KRAS, BRAF and PIK3CA mutations in human colorectal cancer: relationship with metastatic colorectal cancer.

Li HT, Lu YY, An YX, Wang X, Zhao QC.

Oncol Rep. 2011 Jun;25(6):1691-7. doi: 10.3892/or.2011.1217. Epub 2011 Mar 17.

PMID:
21424126
18.

Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes.

Lurkin I, Stoehr R, Hurst CD, van Tilborg AA, Knowles MA, Hartmann A, Zwarthoff EC.

PLoS One. 2010 Jan 21;5(1):e8802. doi: 10.1371/journal.pone.0008802.

19.

Simultaneous identification of 36 mutations in KRAS codons 61 and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit.

Bando H, Yoshino T, Shinozaki E, Nishina T, Yamazaki K, Yamaguchi K, Yuki S, Kajiura S, Fujii S, Yamanaka T, Tsuchihara K, Ohtsu A.

BMC Cancer. 2013 Sep 3;13:405. doi: 10.1186/1471-2407-13-405.

20.

KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2010;10(25):1-49. Epub 2010 Dec 1.

Supplemental Content

Support Center